[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 918
Citations 0
Invited Commentary
September 25, 2019

Safety and Tolerability of Sustained Lipid-Lowering Therapy: Trial Data and Public Perception in a World Where Vaccines and Statins Are About to Collide

Author Affiliations
  • 1Departments of Cardiology and Epidemiology, Erasmus MC–University Medical Center Rotterdam, Rotterdam, the Netherlands
  • 2Department of Clinical Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
JAMA Cardiol. Published online September 25, 2019. doi:https://doi.org/10.1001/jamacardio.2019.3528

Lifetime cumulative exposure to low-density lipoprotein cholesterol (LDL-C) is among the key modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD). Absolute LDL-C levels and the duration of exposure have been repeatedly demonstrated in observational and experimental studies as the driving forces behind the atherosclerotic process. This knowledge is the foundation for an effort to develop long-acting potent LDL-C–lowering drugs to achieve sustained reductions in ASCVD risk.